We hypothesise, therefore, that the primary analysis17 failed to detect the increased capivasertib benefit for participants with PI3K/AKT/PTEN pathway-altered tumours because limitations of the original tests erroneously placed some participants with bone fide pathway-altered tumours in the pathway non-altered subgroup. The gene discussed is PTEN; the disease is neoplasm.